Long-term Follow-up for Safety Evaluation of Subjects Who Participated in the Phase 1 Clinical Trial of CS20AT04(CS20AT04-LN101) in Lupus Nephritis
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Lupus Nephritis
- Sponsor
- Corestemchemon, Inc.
- Enrollment
- 6
- Locations
- 1
- Primary Endpoint
- Percentage of abnormal results of Laboratory tests
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This observation study is planned to evaluate the safety and efficacy of the subjects who received CS20AT04 in the phase 1 clinical trial.
If the subjects who participated in the phase 1 clinical trial voluntarily agree to participate in this observation study, visit 1 and visit 2 will be conducted every 3 months according to the clinical trial protocol until 6 months after administration of CS20AT04 in the phase 1 clinical trial. And Visit 3 after 6 months, Visit 4~Visit 7 will be conducted every 12 months. During each visit, subjects are assessed for the efficacy and occurrence of adverse events.
Detailed Description
Lupus is a representative autoimmune disease that affects the whole body. It is occurred by generation of autoantibody and immune complex due to abnormal activation of the immune cells on the basis of abnormal immune responses. Although about 50% of lupus patients have lupus nephritis, there is no therapeutic product targeting for the lupus nephritis so far. The investigator has performed the pre-clinical and clinical studies using allogenic bone marrow derived mesenchymal stem cells in SLE. CS20AT04 has anti-inflammatory effects, controls activity of immune cells and reduces generation of autoantibodies. So, it is expected to have therapeutic effects on lupus nephritis. Phase 1 clinical trial was conducted as a single center, open-label. The main component of CS20AT04 is bone marrow-derived mesenchymal stem cells. And the risk of tumor formation is low. Through the repeated administration and long-term observation with mouse model, it was confirmed that there was no oncogenicity. In addition, it was confirmed through the cell residual tracking test of the animal model that the in vivo residual period was shorter than 14 days. However, since long-term safety has not been evaluated after administering CS20AT04 to humans, the investigator will confirm the safety of stem cells for up to 5 years according to the risk management plan for stem cell products of the Ministry of Food and Drug Safety and already approved phase 1 clinical trial. Also In the phase 1 clinical trial that only confirmed safety and tolerability for 28 days after administration of CS20AT04, it is difficult to confirm the continuous change of the indicator for evaluating efficacy. So, it is necessary to check the efficacy in this observation study.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A Person who enrolled in a phase 1 clinical trial using CS20AT04 (CS20AT04-LN101) and administered CS20AT04 and has been 3 months.
- •A person who voluntarily consent to participate in this observational study
- •\*Phase I clinical trial Inclusion Criteria
- •Patients with HLA-haplo-matched bone marrow donor is less than 70 years old.
- •Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.
- •Patients had suffered from active renal disease in the past or patients has active renal disease now. Active renal disese should have include below.
- •Spot urine protein/creatinine ratio ≥ 1.0 and ① \>5 RBC/HPF, ② \>5 WBC/HPF, ③ columnar cell.
- •Biopsy confirmed active type III or type IV, or type V lupus nephritis. Patients can be immunosuppressive agent to , steroids, taking, such as anti-Malarials (hydroxychloroquine) in a certain capacity, during the test period, to maintain the same capacity before 4-weeks screening.
- •Patients who consented to participate in the study in writing by themselves or their legal representatives.
Exclusion Criteria
- •A person who do not agree to participate in this follow up observational study among the subjects enrolled in a phase 1 clinical trial using CS20AT
- •\*Phase I clinical trial exclusion criteria
- •Those who do not kidney disease for SLE.
- •Patients with a history of hypersensitivity, such as heavy metal poisoning similar to drug testing and drug ingredients.
- •Patients a history Major organs (kidney, liver, lung, heart) transplant or liver hematopoietic cells / transplant or during of scheduled transplantation clinical trial.
- •patients a history of kidney dialysis or during of the scheduled dialysis clinical trials within 2 weeks prior to the screening.
- •Tested positive for hepatitis B(HBsAg, Anti-HBcAB, HBV-DNA) and hepatitis C(Anti-HCV, HCV-RNA).
- •Patients a history of anaphylactic reaction for the parenteral administration of a monoclonal antibody or contrast agent, a mouse protein or human.
- •Patients whose e-GFR ≤ 30mL/min at screening.
- •Patients with a history of malignancy within 5 years prior to the screening(basal cell carcinoma of skin, squamous cell carcinoma of skin, or cervical intraepithelial neoplasia are excluded).
Outcomes
Primary Outcomes
Percentage of abnormal results of Laboratory tests
Time Frame: up to 57 months after enrollment
The following laboratory tests are performed at each visit * Hematology test: WBC, RBC, Hemoglobin, Hematocrit, Platelet count, WBC Diffcount, ESR * Chemistry test : Total protein, Albumin, Total bilirubin, SGOT(AST), SGPT(ALT), rGTP, Sodium, Potassium, BUN, Creatinine, Glucose, Alkaline Phosphatase, Chloride, Total cholesterol, Triglyceride, Uric Acid , CPK, LDH, CRP, Adolase * Urine analysis : Protein, Creatinine, Glucose, Urobilinogen, WBC, RBC, Urine Sediment, Creatinine, Urine albumin creatinine ratio, Urine protein creatinine ratio
Incidence of abnormal results of Physical examination
Time Frame: up to 57 months after enrollment
Physical examination is performed at each visit. If clinically significant abnormal findings are recorded in the CRF and collected as AEs.
Incidence of adverse events
Time Frame: up to 57 months after enrollment
After the completion of the CS20AT04-LN101 phase 1 trail, new adverse events, including tumor are assessed and detailed information is collected at each visit.
Percentage of abnormal Vital signs
Time Frame: up to 57 months after enrollment
Percentage of abnormal Blood pressure (mmHg) and Pulse rate (beat per minute)
Secondary Outcomes
- SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2000)(up to 57 months after enrollment)
- BILAG 2004 (British Isles Lupus Assessment Group 2004)(up to 57 months after enrollment)
- Disease activity assessed by PGA (Physician Global Assessment)(up to 57 months after enrollment)
- SDI (Systemic Lupus International Collaborating Clinics/Americans College of Rheumatology (SLICC/ACR) Damage Index(up to 57 months after enrollment)